A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis
Andreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, Jonathan I Silverberg, Claire Birrell, Christopher Kell, Koustubh Ranade, Michelle Dawson, Rene van der Merwe
Abstract not available.
Disclosures: Study sponsored by LEO Pharma
Copyright 2018 SKIN
tralokinumab; atopic dermatitis; biologic therapy
Abstract - 219 Poster PDF - 170
- There are currently no refbacks.